[New perspectives in the management of dyslipidemia and the role of PCSK9 inhibitors].

Source: PubMed, NCBI / U.S. National Library of Medicine

SemergenEspinosa-García S, Betancor-Pérez C, Larrañaga-Zulaica Y, et al.Published 7/7/2026Last synced 7/8/2026Status: syncedPMID: 42413166DOI: 10.1016/j.semerg.2026.102799

Cardiovascular diseases continue to be the leading cause of morbidity and mortality worldwide. Reducing LDL cholesterol (LDL-c) is one of the fundamental pillars of cardiovascular prevention; however, a significant percentage of patients do not reach the recommended therapeutic targets with first-line treatment. PCSK9 inhibitors have demonstrated significant reductions in LDL-c and decreased cardiovascular events in high- and very high-risk patients. The 2025 update of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guidelines for the management of dyslipidemias reinforces the concept of the earlier and the lower, the better, as well as the need for early combination therapies.

Educational only

This information is for general education and is not medical advice. Always talk to a licensed U.S. clinician about your situation, medications, or treatment decisions.